The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study

The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study

As indications for sodium-glucose co-transporter-2 inhibitors (SGLT2i) are expanding, a growing number of older adults have become candidates for treatment. We studied the safety profile of SGLT2i among older adults. A retrospective, pharmacovigilance study of the FDA's global database of safet...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiovascular Diabetology 2023-01, Vol.22 (1), p.16-10, Article 16
Hauptverfasser: Goldman, Adam, Fishman, Boris, Twig, Gilad, Raschi, Emanuel, Cukierman-Yaffe, Tali, Moshkovits, Yonatan, Pomerantz, Alon, Ben-Zvi, Ilan, Dankner, Rachel, Maor, Elad
Format: Artikel
Sprache:eng
Schlagworte:
Adverse events
Age
Aged
Amputation
Analysis
Clinical trials
Complications and side effects
Dehydration
Dextrose
Diabetes
Diabetes mellitus
Diabetes Mellitus, Type 2 - diagnosis
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - epidemiology
Diabetes therapy
Diabetic ketoacidosis
Ejection fraction
Fournier gangrene
Fractures
Gangrene
Glucose
Glucose transporter
Heart failure
Humans
Hypoglycemia
Hypoglycemic agents
Hypotension
Insulin
Insulin - therapeutic use
Ketoacidosis
Marketing
Middle Aged
Older adults
Older people
Pharmacovigilance
Population
Retrospective Studies
Safety
Sex ratio
Sodium
Sodium-glucose co-transporter-2 inhibitors
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
Surveillance
Symporters
Syncope
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:As indications for sodium-glucose co-transporter-2 inhibitors (SGLT2i) are expanding, a growing number of older adults have become candidates for treatment. We studied the safety profile of SGLT2i among older adults. A retrospective, pharmacovigilance study of the FDA's global database of safety reports. To assess reporting of pre-specified adverse events following SGLT2i among adults (
ISSN:1475-2840
1475-2840
DOI:10.1186/s12933-023-01743-5